Galapagos NV (spons. ADRs) Aktie

23,20 EUR ±0,00 EUR ±0,00 %

31.03.2025

STU

25,12 USD -0,35 USD -1,36 %

31.03.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

KGV22,62Div. Rendite0,00%

WKNA0YGNJ

ISINUS36315X1019

SymbolGLPG

Galapagos NV (spons. ADRs) Aktien News

Sortieren:Datum Meistgelesen

27.03.25GlobeNewswireGalapagos Publishes 2024 Annual Report and Announces Annual Shareholders’ Meeting

24.02.25GlobeNewswireGalapagos to Present at Upcoming Investor Conferences

17.02.25GlobeNewswireGalapagos receives transparency notification and 13D filing from Tang Capital

WerbungGalapagos NV (spons. ADRs)-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

12.02.25GlobeNewswireGalapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

08.01.25GlobeNewswireGalapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

07.01.25GlobeNewswireGalapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

07.12.24GlobeNewswireGalapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

05.11.24GlobeNewswireGalapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

30.10.24GlobeNewswireGalapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

07.10.24GlobeNewswireGalapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

30.09.24GlobeNewswireGalapagos receives transparency notification from EcoR1 Capital

16.09.24GlobeNewswireGalapagos receives transparency notification from EcoR1 Capital

03.09.24GlobeNewswireGalapagos receives transparency notification from FMR LLC

23.08.24GlobeNewswireGalapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

20.08.24GlobeNewswireGalapagos receives transparency notification from FMR LLC

01.08.24GlobeNewswireGalapagos reports half-year 2024 financial results and provides second quarter business update

01.08.24PR NewswireBridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology

14.06.24GlobeNewswireGalapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

30.05.24GlobeNewswireGalapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future so

16.05.24GlobeNewswireGalapagos creates new subscription right plans

15.05.24GlobeNewswireGalapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.

02.05.24GlobeNewswireGalapagos reports first quarter 2024 financial results

30.04.24GlobeNewswireGalapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024

04.04.24GlobeNewswireGalapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024

28.03.24GlobeNewswireGalapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings

26.03.24GlobeNewswireGalapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board

22.02.24GlobeNewswireGalapagos announces full year 2023 results and outlook for 2024

15.02.24GlobeNewswireGalapagos presents at EBMT-EHA annual meeting 2024

31.01.24GlobeNewswireGalapagos completes transaction to transfer Jyseleca® business to Alfasigma

04.01.24GlobeNewswireGalapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.

03.01.24GlobeNewswireGalapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology

03.01.24PR NewswireBridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets

02.01.24GlobeNewswireGalapagos signs agreement to transfer Jyseleca® business to Alfasigma

19.12.23GlobeNewswireGalapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301

09.12.23GlobeNewswireGalapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101

07.12.23GlobeNewswireGalapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023

06.11.23PR NewswireLandmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care

02.11.23GlobeNewswireGalapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023

30.10.23GlobeNewswireGalapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma

19.09.23GlobeNewswireGalapagos appoints Simon Sturge to its Board of Directors

Galapagos NV (spons. ADRs) News

Galapagos NV (spons. ADRs) News: auf dieser Seite finden Sie alle Galapagos NV (spons. ADRs) News und Nachrichten zur Galapagos NV (spons. ADRs) Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Galapagos NV (spons. ADRs) News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Galapagos NV (spons. ADRs) News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.